NovaBay Pharmaceuticals, Inc. (NYSE:NBY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

According to Zacks, “NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. “

Several other equities research analysts have also recently issued reports on the stock. Roth Capital initiated coverage on shares of NovaBay Pharmaceuticals in a research note on Monday, June 5th. They set a “buy” rating and a $5.50 target price on the stock. Maxim Group reiterated a “hold” rating on shares of NovaBay Pharmaceuticals in a report on Saturday, May 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $7.00.

Shares of NovaBay Pharmaceuticals (NYSE:NBY) opened at 4.70 on Friday. NovaBay Pharmaceuticals has a 52 week low of $2.12 and a 52 week high of $5.29. The stock has a 50 day moving average of $3.68 and a 200 day moving average of $3.57. The stock’s market cap is $71.95 million.

TRADEMARK VIOLATION NOTICE: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/05/novabay-pharmaceuticals-inc-nysenby-lowered-to-sell-at-zacks-investment-research.html.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Analyst Recommendations for NovaBay Pharmaceuticals (NYSE:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.